Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
BörsenkürzelEXAS
Name des UnternehmensExact Sciences Corp
IPO-datumJan 30, 2001
CEOMr. Kevin T. Conroy
Anzahl der mitarbeiter6900
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
Addresse5505 Endeavor Lane
StadtMADISON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl53719
Telefon16082845700
Websitehttps://www.exactsciences.com/
BörsenkürzelEXAS
IPO-datumJan 30, 2001
CEOMr. Kevin T. Conroy
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten